The goal of the NCI National Clinical Trials Network (NCTN) is to develop and conduct state-of-the-art cancer treatment and advanced imaging clinical trials, especially large, definitive multi-institutional trials evaluating new cancer therpies and related clinical approaches. NCTN Lead Academic Participating Sites (LAPS) are one component of this network and will provide scientific leadership in the development and conduct of NCTN clinical trials in association with one or more adult Network Groups as well as substantial accrual to clinical trials conducted across the entire NTCN. The Fred Hutchinson Cancer Research Center (FHCRC) is among the nation's leading cancer centers and is the only NCI-designated comprehensive cancer research center serving the WWAMI (Washington, Wyoming, Alaska, Montana and Idaho) region. The broad and deep pre-clinical and clinical research programs at the FHCRC will support the NCTN Program in three major ways: (1) The scientific expertise of the members of the FHCRC will continue to contribute to the leadership of the NCTN program through their activities directly at the NCI and in SWOG, NRG and ACRIN. (2) The innovative pre-clinical and clinical research studies at the FHCRC will provide the preliminary information necessary to shape the next generation of cooperative group trials. (3) The large patient base at the FHCRC combined with expert clinicians and clinical trials infrastructure will assure substantial accrual to NCTN trials. Fred Hutchinson Cancer Research Center and its partners are committed to the goals of the National Clinical Trials Network (NCTN) and will work to provide leadership for our nation's clinical trials network.
In 2012, approximately 1.64 million individuals in the United States will be diagnosed with cancer and 577,000 will die of the disease. Clearly, new approaches to cancer prevention, diagnosis, and treatment are needed and these will only come from new insights achieved through research. As one of the leading cancer research centers in the country, the Fred Hutchinson Cancer Research Center can help provide leadership for our nation's clinical trials network.
|Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522|
|Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465|
|Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40|
|Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641|
|Qu, Xiaoyu; Othus, Megan; Davison, Jerry et al. (2017) Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials. Cancer 123:2472-2481|
|Kalinsky, Kevin; Lee, Sandra; Rubin, Krista M et al. (2017) A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer 123:2688-2697|
|Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952|
|Lara Jr, Primo N; Moon, James; Redman, Mary W et al. (2016) Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. Clin Lung Cancer 17:113-8.e1-2|
|Halabi, Susan; Kelly, William Kevin; Ma, Hua et al. (2016) Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol 34:1652-9|
|Achille, Nicholas J; Othus, Megan; Phelan, Kathleen et al. (2016) Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients. Leuk Res 42:68-74|
Showing the most recent 10 out of 28 publications